Clinical Trial Update: bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma [NA]

View source ↗

Summary

A clinical trial is evaluating the combination of bTAE-HAIC with Lenvatinib and Sintilimab for infiltrative hepatocellular carcinoma, with recruitment currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Liver Diseases, Hepatocellular Carcinoma | NA | Status: RECRUITING